Pulmaquin, an inhaled liposomal ciprofloxacin, is currently undergoing two Phase 3 clinical studies to determine its safety and effectiveness as an inhaled formulation for the treatment of patients with non-cystic fibrosis bronchiectasis, cystic fibrosis or non-tuberculous mycobacteria.

Changing the Tide of Antibiotic-Resistant Infections